All > Metastatic Lung Cancer > Small Cell Lung Cancer

ETOPOSIDE - Study for Small Cell Lung Cancer

Medicine Invention Design, Inc. (MIDI) - IORG0007849, North Bethesda, MD
Small Cell Lung CancerETOPOSIDE - Study - Drug
Eligibility
22 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This trial will explore the relationship between a patient's genetic makeup and how well they respond to the drug etoposide, as well as any side-effects they may experience.

Eligible Conditions
  • Small Cell Lung Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Similar Trials

1
Group 3: Quadrivalent Influenza mRNA Vaccine MRT5410 high dose
1
ATL001
1
Pembrolizumab

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Duration at least 180 days

Day 180
Find Etoposide Drug Targets' SNP Genotypes which are effectiveness-associated and which are risk-associated.
Day 90
Find Etoposide Drug Targets' SNP Genotypes which are effectiveness-associated, and which are risk-associated.

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Group 3: Quadrivalent Influenza mRNA Vaccine MRT5410 high dose
1
ATL001
1
Pembrolizumab

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2 Treatment Groups

ETOPOSIDE - Study
1 of 2
ETOPOSIDE - Usual
1 of 2

Experimental Treatment

600 Total Participants · 2 Treatment Groups

Primary Treatment: ETOPOSIDE - Study · No Placebo Group · Phase 2

ETOPOSIDE - Study
Drug
Experimental Group · 1 Intervention: ETOPOSIDE - Study · Intervention Types: Drug
ETOPOSIDE - Usual
Drug
Experimental Group · 1 Intervention: ETOPOSIDE - Usual · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: duration at least 180 days

Who is running the clinical trial?

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairLead Sponsor
3 Previous Clinical Trials
60 Total Patients Enrolled
Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB ChairLead Sponsor
3 Previous Clinical Trials
60 Total Patients Enrolled
HAN XU, M.D. / Ph.D.Study ChairMedicine Invention Design, Inc. (MIDI) - IORG0007849
HAN XU, M.D., Ph.D.Study DirectorMedicine Invention Design, Inc. (MIDI) - IORG0007849
3 Previous Clinical Trials
60 Total Patients Enrolled

Eligibility Criteria

Age 22 - 75 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
We are looking for 600 patients with small cell lung cancer who can have a biopsy of their lung tissue.
The study requires you to participate for a minimum of 180 days (about 6 months).
The study aims to recruit 300 patients with small cell lung cancer who are currently receiving a standard treatment of combined chemotherapy with certain drugs. These patients will also undergo a lung tissue biopsy, which is a common procedure.
The study is looking for 300 patients with small cell lung cancer who are currently being treated with a combination of chemotherapy drugs. These patients will be randomly assigned to two groups and will undergo a lung tissue biopsy.
You have been diagnosed with small cell lung cancer.
You have been diagnosed with small cell lung cancer through a biopsy of lung tissue.
You can undergo a lung tissue biopsy for small cell lung cancer testing.
The selection process for participants will be random, and the study is designed so that neither the participant nor the researcher knows who is receiving the treatment and who is receiving a placebo.
You have a medical condition that can be measured during the study.
Your organs are working properly.
References

Frequently Asked Questions

Would it be possible for me to participate in this clinical trial?

"This clinical trial is looking for 600 participants with small cell lung carcinoma, aged 22 to 75. In order to be eligible, patients must have had the condition for at least 180 days and must be able to have a lung tissue biopsy. Additionally, the following criteria must be met: 1. Clinical diagnosis of Small Cell Lung Cancer (SCLC), 2. Clinical lung tissue biopsy diagnosis of SCLC, 3. Suitable for enough lung tissue biopsy of SCLC, 4. Random and double blind, 5. Measurable disease, 6. Adequate organ functions." - Anonymous Online Contributor

Unverified Answer

What conditions does ETOPOSIDE - Study help treat?

"ETOPOSIDE - This medication is most frequently utilized to manage [small cell lung cancer](https://www.withpower.com/clinical-trials/small-cell-lung-cancer) (sclc). Additionally, it can be useful in treating metastatic thymic cancer, leukemia, myelocytic, acute, and advance directives." - Anonymous Online Contributor

Unverified Answer

Can people below the age of 20 participate in this clinical research?

"The age limit for this study are individuals who are at least 22 but no older than 75." - Anonymous Online Contributor

Unverified Answer

What does the research say about using etoposide to treat patients?

"There are presently 322 clinical trials underway researching the efficacy of ETOPOSIDE - Study. 95 of those are in the final Phase 3. Many of these studies are based in Houston, Texas, but there are a total of 15464 locations running these trials." - Anonymous Online Contributor

Unverified Answer

Do we have the regulatory go-ahead to use ETOPOSIDE in this research?

"ETOPOSIDE - Study has been scored a 3 for safety by our team at Power. This is due to this being a Phase 3 trial, which signifies that there is data affirming its efficacy as well as multiple rounds of data affirming its safety." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top